SCHEMBL8611268

SCHEMBL8611268

CCc1ccc(C2CCCCN2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 3/20 0.47
CYP2C19 P33261 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
CHRNB2 P17787 2/20 0.47
CHRNA7 P36544 2/20 0.47
CHRNA4 P43681 2/20 0.47
POLB P06746 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C9 P11712 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CYP2A6 P11509 1/20 0.47
MKNK1 Q9BUB5 1/20 0.43
AURKA O14965 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CHRM2 P08172 3/20 0.38
CHRM4 P08173 2/20 0.38
CHRM5 P08912 2/20 0.38
CHRM1 P11229 2/20 0.38
CHRM3 P20309 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6178200 0.95 MKNK1 (0.48) CYP2D6CYP2C19MEN1KMT2ACHRNB2
SCHEMBL716893 0.95 MKNK1 (0.48) CYP2D6CYP2C19MEN1KMT2ACHRNB2
SCHEMBL22918239 0.85 CHRNB2 (0.41) CHRNB2CHRNA4SMN1; SMN2CYP2A6
SCHEMBL27351589 0.82 MEN1 (0.47) CYP2D6CYP2C19MEN1KMT2ACHRNB2
SCHEMBL1652841 0.82 MEN1 (0.47) CYP2D6CYP2C19MEN1KMT2ACHRNB2
SCHEMBL28064867 0.81 MEN1 (0.44) CYP2D6CYP2C19MEN1KMT2ACHRNB2
SCHEMBL3717223 0.79 MEN1 (0.51) CYP2D6CYP2C19MEN1KMT2ACHRNB2
SCHEMBL23891896 0.78 CYP2D6 (0.44) CYP2D6CYP2C19MEN1KMT2ACHRNB2
SCHEMBL8541954 0.78 MEN1 (0.50) CYP2D6CYP2C19MEN1KMT2ACHRNB2
SCHEMBL7672102 0.78 MEN1 (0.50) CYP2D6CYP2C19MEN1KMT2ACHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150197524-A1 ORGANIC COMPOUNDS LI PENG (US) 2015-07-16 US disclosed
US-8846693-B2 Optionally substituted pyrazolo[3,4-d]pyrimidine-4,6-diones INTRA-CELLULAR THERAPIES, INC. (US) 2014-09-30 US disclosed
US-20130023523-A1 PYRIDAZINO[4,5-D]PYRIMIDIN-5(6H)-ONE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2013-01-24 US disclosed
EP-0832106-A2 COMPOUNDS HAVING BRADYKININ ANTAGONISTIC ACTIVITY AND MU-OPIOID AGONISTIC ACTIVITY CORTECH, INC. (US) 1998-04-01 EP disclosed
WO-1996039425-A2 COMPOUNDS HAVING BRADYKININ ANTAGONISTIC ACTIVITY AND MU-OPIOID AGONISTIC ACTIVITY CORTECH, INC. (US) 1996-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150197524-A1 ORGANIC COMPOUNDS OPRD1, HTR1D, DRD1 CYP2D6 235/4885CYP2C19 128/4885MEN1 4689/4885
US-20130023523-A1 PYRIDAZINO[4,5-D]PYRIMIDIN-5(6H)-ONE INHIBITORS OF KINASES WEE1, WEE2, CDK1 CYP2D6 1313/4885CYP2C19 1272/4885MEN1 1260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.